Since the neo-liberal revolution of the 1980s pharmaceutical companies have super charged their profiteering, at the expense of patients. In this edited extract from his new book Pharmanomics, Nick Dearden explains how and looks to the solutions.
In 2018, investment giant Goldman Sachs asked a provocative question: “Is curing patients a sustainable business model?” They were referring to the growth of gene therapy, which holds out the promise of giving patients a ‘one shot cure’ for all manner of conditions.
